Furthermore, this platform co-delivering Cas9 mRNA/VEGFR2 sgRNA effectively reduced VEGFR2 expression in lung endothelial cells, demonstrating its therapeutic potential in antiangiogenic therapy for suppressing tumor growth and prolonging mice survival within a lung tumor model of female mice, substantially outperforming a gold standard lung-tropic MC3/DOTAP LNP system. The gene discussed is KDR; the disease is neoplasm.